We are a pharmaceutical company currently engaged in the research and
development of innovative pharmaceutical solutions, including an oral insulin
capsule to be used for the treatment of individuals with diabetes, and the use
of orally ingestible capsules or pills for delivery of other polypeptides.
Oral insulin: We are seeking to revolutionize the treatment of diabetes through
our proprietary flagship product, an orally ingestible insulin capsule
(ORMD-0801). Having completed Phase IIa clinical trials in patients with both
type 1 and type 2 diabetes, we initiated a Phase IIb clinical trial on
approximately 180 type 2 diabetic patients that is being conducted in
approximately 30 sites in the United States, beginning in June 2015. This
double-blind, randomized, 28-day study clinical trial is conducted under an
Investigational New Drug application, or IND, with the U.S. Food and Drug
Administration, or FDA.